Novo Nordisk Shares Face Mounting Pressure as Analyst Warns of Further Declines
Published on 12/01/2025 at 13:15 | Redaktion boerse-global.de
A leading financial institution has issued a stark warning for investors in Novo Nordisk, suggesting the Danish pharmaceutical giant’s stock may continue its precipitous fall. Despite a year-to-date loss of approximately 50% in market capitalization, Jefferies analysts believe the bottom has not yet been reached.
In a move that dampened market sentiment, Jefferies resumed coverage of Novo Nordisk with a stark “Underperform” rating. Analyst Michael Leuchten set a price target of 270 Danish Krone (DKK), implying a potential further decline of about 14% from current trading levels. The firm’s analysis points to two core concerns: the continued absence of a valuation floor despite the year’s severe losses and looming structural Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
